Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Alnylam Pharmaceuticals Inc (ALNY - Analyst Report) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington's disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington's disease. Further, ALN-HTT was well tolerated in these studies.

ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT - Analyst Report) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food & Drug Administration (FDA) will allow the candidate to enter early stage clinical trials.

Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancer through existing or future partnerships. Alnylam’s core product strategy however is Alnylam 5x15 which aims at developing products for treating genetically defined diseases with unmet medical needs using the ground-breaking RNAi technology. Alnylam expects to have five such RNAi therapeutic programs in advanced clinical development by the end of 2015. Four programs are in pre-clinical/clinical stages of development including ALN-PCS (for hypercholesterolemia), second generation ALN-TTR (ATTR), ALN-HPN (refractory anemia) and ALN-APC (hemophilia). ALN-HTT makes up the fifth candidate.

Our Recommendation

We currently have an Outperform recommendation on Alnylam. The stock carries a Zacks #2 Rank (“Buy”) in the short term. We like the company’s “5X15” initiative and also the pipeline progress at Alnylam. We believe that 2012 will be an important year for the company due to significant clinical catalysts. Moreover, the company has collaborated with some big pharmaceutical players, such as Roche (RHHBY - Analyst Report), Biogen (BIIB - Analyst Report), Medtronic, Takeda, Kyowa Hakko Kirin, Cubist Pharmaceuticals (CBST - Analyst Report) and Isis Pharmaceuticals (ISIS - Analyst Report), to further develop and utilize its core technology. These partnerships further validate the potential and viability of the RNAi approach.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%